-

Longhorn Vaccines and Diagnostics Appoints Zoe Silver as Senior Vice President of Genomics & Diagnostics

Silver has decades of experience in shepherding products, including molecular diagnostics, to commercialization within the medical and consumer industries

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics LLC, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, announced today that Zoe Silver has joined the company as Senior Vice President of Genomics & Diagnostics. Silver brings over 25 years of experience as a senior level executive in commercialization that spans the medical and consumer industries. He will lead the expansion of Longhorn’s PrimeStore Molecular Transport Medium (MTM)® and other diagnostic tools into new applications in genetics, microbiome, and new pathogen sample types.

“We have achieved immense success in the last few years in scaling our PrimeStore MTM® business, from being called upon by the FDA to support Covid-19 testing to expanding our diagnostic capabilities in animal health and plant pathogens. Zoe will help our team expand our diagnostics side beyond PrimeStore MTM with a One Health approach,” said Longhorn CEO Gerald W. Fischer, MD. “PrimeStore MTM has been used to surveil, track and diagnose pathogens ranging from influenza and tuberculosis to African swine fever and avian influenza, which demonstrates our ability to rapidly deploy critical tools to address to public health issues. Under Zoe’s leadership we can continue to work with governments, reference and other laboratories, healthcare institutions and industry leaders to prevent the next outbreak.”

In his role, Silver will develop and expand partnerships with leading high throughput laboratories that are in need of safe and effect tools to test for infectious pathogens. These tools include PrimeStore MTM which is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. Silver will also lead the launch of new products onto the genomics and diagnostic markets.

Silver has dedicated his career to improving patient outcomes through the introduction and sale of effective medical solutions to life sciences, clinical diagnostics and healthcare markets. He has a proven track record within molecular diagnostics, having commercialized market leading products while delivering customer-centric, market driven programs to the industry. He most recently served as Senior Vice President of Genomics and Diagnostics at SiO2 with similar roles in marketing at Tecan and BSN Medical, and in marketing leadership roles at White Hot Pizza and Ben & Jerrys.

For more information about Longhorn, visit www.LHNVD.com.

About Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines and Diagnostics LLC is a One Health company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn caters to both in order to surveil, diagnose, prevent and treat the next infectious disease.

Longhorn’s core product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting virus samples, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization.

Contacts

Longhorn Vaccines and Diagnostics LLC
Jeffrey Fischer
Email: jeff@lhnvd.com

Media
Alexis Feinberg – ICR Westwicke PR
Email: alexis.feinberg@westwicke.com

Longhorn Vaccines and Diagnostics LLC


Release Versions

Contacts

Longhorn Vaccines and Diagnostics LLC
Jeffrey Fischer
Email: jeff@lhnvd.com

Media
Alexis Feinberg – ICR Westwicke PR
Email: alexis.feinberg@westwicke.com

More News From Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines & Diagnostics' PrimeStore® MTM Validated with New Data for Large-Scale, Global TB Screening

GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines & Diagnostics (“Longhorn”), a One Health company developing antibodies and diagnostic tools for global public health and zoonosis concerns, today announced compelling new data validating the utility of various swab samples processed with PrimeStore® MTM for tuberculosis (TB) detection in both pediatric clinical settings and large-scale community screening. The findings were divided into two presentations and presented by TB and viral inf...

Longhorn Vaccines & Diagnostics to Present Data on Large-Scale TB Screening with PrimeStore® MTM at The Union World Conference on Lung Health 2025

GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines & Diagnostics (“Longhorn”), a One Health company developing antibodies and diagnostic tools for global public health and zoonosis concerns, announced today that the University of Pretoria will present two studies around alternative sample tuberculosis (TB) screening using PrimeStore® MTM, an FDA-cleared sample medium for inactivating both RNA and DNA, at The Union World Conference on Lung Health 2025. The abstract presentations will high...

Longhorn Vaccines and Diagnostics to Present Late-Breaking Poster at ESCMID 2025 on LHNVD-303 to Treat and Prevent Antimicrobial Resistance

GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics (“Longhorn”) today announced it will present a late-breaking poster at the 6th ESCMID Conference on Vaccines supporting the breath of a single, conserved-target antibody to address the bacteria associated with antimicrobial resistance (AMR) and inflammation from gram-positive and gram-negative pathogens. The presentation will feature the company’s anti-peptidoglycan (PGN) monoclonal antibody, the core of LHNVD-303, for the pr...
Back to Newsroom